MAIA Biotechnology Total Debt vs. EBITDA
| MAIA Stock | USD 2.13 0.03 1.39% |
For MAIA Biotechnology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of MAIA Biotechnology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well MAIA Biotechnology utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between MAIA Biotechnology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of MAIA Biotechnology over time as well as its relative position and ranking within its peers.
MAIA |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MAIA Biotechnology. If investors know MAIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MAIA Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.34) | Return On Assets (1.07) | Return On Equity (5.60) |
The market value of MAIA Biotechnology is measured differently than its book value, which is the value of MAIA that is recorded on the company's balance sheet. Investors also form their own opinion of MAIA Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is MAIA Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MAIA Biotechnology's market value can be influenced by many factors that don't directly affect MAIA Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MAIA Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if MAIA Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MAIA Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
MAIA Biotechnology EBITDA vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining MAIA Biotechnology's current stock value. Our valuation model uses many indicators to compare MAIA Biotechnology value to that of its competitors to determine the firm's financial worth. MAIA Biotechnology is rated below average in total debt category among its peers. It is rated below average in ebitda category among its peers . At present, MAIA Biotechnology's EBITDA is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the MAIA Biotechnology's earnings, one of the primary drivers of an investment's value.MAIA Total Debt vs. Competition
MAIA Biotechnology is rated below average in total debt category among its peers. Total debt of Health Care industry is now estimated at about 754.77 Million. MAIA Biotechnology maintains roughly 7.09 Million in total debt contributing less than 1% to equities under Health Care industry.
MAIA EBITDA vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
MAIA Biotechnology |
| = | 7.09 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
MAIA Biotechnology |
| = | (20.18 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
MAIA EBITDA Comparison
MAIA Biotechnology is currently under evaluation in ebitda category among its peers.
MAIA Biotechnology Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in MAIA Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, MAIA Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of MAIA Biotechnology's change in net profit over the period of time. It can combine multiple indicators of MAIA Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -16.3 K | -17.1 K | |
| Operating Income | -20.2 M | -19.2 M | |
| Income Before Tax | -19.8 M | -20.8 M | |
| Total Other Income Expense Net | 409.5 K | 429.9 K | |
| Net Loss | -11.3 M | -11.8 M | |
| Net Loss | -19.8 M | -18.8 M | |
| Income Tax Expense | -176.7 K | -167.9 K | |
| Net Interest Income | 27.6 K | 29 K | |
| Interest Income | 34.5 K | 36.2 K | |
| Net Loss | -19.8 M | -20.8 M | |
| Change To Netincome | 7.7 M | 5.4 M | |
| Net Loss | (1.49) | (1.57) | |
| Income Quality | 0.66 | 0.36 | |
| Net Income Per E B T | 0.90 | 0.79 |
MAIA Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on MAIA Biotechnology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of MAIA Biotechnology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the MAIA Biotechnology's important profitability drivers and their relationship over time.
Use MAIA Biotechnology in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if MAIA Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MAIA Biotechnology will appreciate offsetting losses from the drop in the long position's value.MAIA Biotechnology Pair Trading
MAIA Biotechnology Pair Trading Analysis
The ability to find closely correlated positions to MAIA Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace MAIA Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back MAIA Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling MAIA Biotechnology to buy it.
The correlation of MAIA Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as MAIA Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if MAIA Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for MAIA Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your MAIA Biotechnology position
In addition to having MAIA Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Corporate Bonds Funds Thematic Idea Now
Corporate Bonds Funds
Funds or Etfs investing in different types of corporate debt instruments. The Corporate Bonds Funds theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corporate Bonds Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Correlation Analysis. For information on how to trade MAIA Stock refer to our How to Trade MAIA Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
To fully project MAIA Biotechnology's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of MAIA Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include MAIA Biotechnology's income statement, its balance sheet, and the statement of cash flows.